Skip to main content
. 2022 Jan 15;19(1):74–89. doi: 10.20892/j.issn.2095-3941.2020.0218

Figure 2.

Figure 2

Performance evaluation of the repurposing model. (A–B) The ROC curves of the validation set with the changes in the weighting parameters and restart probability. (C–D) The ROC curves of the model when prior knowledge of the drug-disease links was excluded and included.